EQL Pharma AB (publ) (STO:EQL)
Sweden
· Delayed Price · Currency is SEK 50.50
-0.20 (-0.39%)
At close: Dec 3, 2025
EQL Pharma AB Revenue
EQL Pharma AB had revenue of 86.38M SEK in the quarter ending September 30, 2025, with 1.33% growth. This brings the company's revenue in the last twelve months to 399.07M, up 26.14% year-over-year. In the fiscal year ending March 31, 2025, EQL Pharma AB had annual revenue of 373.52M with 41.39% growth.
Revenue (ttm)
399.07M
Revenue Growth
+26.14%
P/S Ratio
3.70
Revenue / Employee
18.14M
Employees
21
Market Cap
1.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 373.52M | 109.35M | 41.39% |
| Mar 31, 2024 | 264.17M | 4.26M | 1.64% |
| Mar 31, 2023 | 259.91M | -149.84M | -36.57% |
| Mar 31, 2022 | 409.75M | 230.61M | 128.73% |
| Mar 31, 2021 | 179.14M | 107.11M | 148.70% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 27.85B |
| Getinge AB | 35.85B |
| Sectra AB | 3.37B |
| Camurus AB | 2.35B |
| Medicover AB | 25.67B |
| Asker Healthcare Group AB | 16.41B |
| BioArctic AB | 1.92B |
| AddLife AB | 10.53B |